Table 4

Extracranial response rate to ipilimumab–nivolumab (I–N)

Extracranial metabolic response, no. (%)First-line I–N (n=17)Second-line and third-line I–N (n=9)P value
Complete metabolic response12 (70.6)0 (0.0)
Partial metabolic response2 (11.8)1 (11.1)
Stable metabolic disease0 (0.0)0 (0.0)
Progressive metabolic disease3 (17.6)8 (88.9)
Metabolic disease control rate14 (82.4)1 (11.1)0.0008
Objective metabolic response rate14 (82.4)1 (11.1)
  • Extracranial responses assessed by Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST). For the first-line ipilimumab-nivolumab (I–N) group, four patients had no measurable PERCIST disease at baseline, three patients had no follow-up FDG-PET (although two of these patients had RECIST progression) and one patient did not have a baseline FDG-PET. For the second/third line I–N group, 16 patients had no measurable PERCIST disease at baseline and five patients had no follow-up FDG-PET. All five patients that did not have a follow-up FDG-PET exhibited intracranial progression.

  • FDG-PET, F-18 fluorodeoxyglucose positron emission tomography; I-N, ipilimumab–nivolumab; RECIST, Response Evaluation Criteria in Solid Tumors.